Thrombus-targeted perfluorocarbon-containing liposomal bubbles for enhancement of ultrasonic thrombolysis: In vitro and in vivo study

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 8, 2013, Pages 1565-1573

  Hagisawa, K ^a   Nishioka, T ^b   Suzuki, R ^c   Maruyama, K ^c   Takase, B ^a   Ishihara, M ^a   Kurita, A ^a   Yoshimoto, N ^b   Nishida, Y ^a   Iida, K ^d   Luo, H ^d   Siegel, R J ^d  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c TEIKYO UNIVERSITY   (Japan)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Drug targeting; Liposomes; RGD peptide; Thrombolytic therapy; Ultrasound

Indexed keywords

BUBBLE LIPOSOME; FLUOROCARBON; LIPOSOME; PERFLUTREN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANGIOGRAPHY; ANIMAL MODEL; ANIMAL TISSUE; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOT LYSIS; CLINICAL PROTOCOL; EXPERIMENTAL RABBIT; FEMORAL ARTERY; FIBRINOLYSIS; HUMAN; HUMAN TISSUE; ILIAC ARTERY; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RECANALIZATION; ULTRASONIC THROMBOLYSIS; ULTRASOUND; WEIGHT REDUCTION;

DRUG TARGETING; LIPOSOMES; RGD PEPTIDE; THROMBOLYTIC THERAPY; ULTRASOUND;

ANGIOGRAPHY; ANIMALS; FIBRINOLYSIS; FLUOROCARBONS; GASES; HUMANS; INFUSIONS, INTRAVENOUS; LIPOSOMES; OLIGOPEPTIDES; RABBITS; THROMBOLYTIC THERAPY; THROMBOSIS; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; ULTRASONICS;

EID: 84881590723     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12321     Document Type: Article

References (42)

1. Mizuno K, Miyamoto A, Satomura K, Kurita A, Arai T, Sakurada M, Yanagida S, Nakamura H. Angioscopic coronary macromorphology in patients with acute coronary disorders. Lancet 1991; 337: 809-12.
2. Fuster V, Fayad ZA, Badimon JJ. Acute coronary syndromes: biology. Lancet. 1999; 353: SII5-9.
3. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110: 588-636.
4. Stone GW, Grines CL, Rothbaum D, Browne KF, O'Keefe J, Overlie PA, Donohue BC, Chelliah N, Vlietstra R, Catlin T, O'Neill WW. Analysis of the relative costs and effectiveness of primary angioplasty versus tissue-type plasminogen activator: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. The PAMI Trial Investigators. J Am Coll Cardiol 1997; 29: 901-7.
5. Schomig A, Kastrati A, Dirschinger J, Mehilli J, Schricke U, Pache J, Martinoff S, Neumann FJ, Schwaiger M. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med 2000; 343: 385-91.
6. Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czlonkowska A, Kobayashi A, Ricci S, Murray V, Berge E, Slot KB, Hankey GJ, Correia M, Peeters A, Matz K, Lyrer P, Gubitz G, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the Third International Stroke Trial [IST-3]): a randomised controlled trial [published correction appears in Lancet. 2012; 380: 730]. Lancet 2012; 379: 2352-63.
7. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44: 870-947.
8. Wahlgren N, Ahmed N, Dávalos A, Hacke W, Millán M, Muir K, Roine RO, Toni D, Lees KR; SITS investigators. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008; 372: 1303-9.
9. Luo H, Birnbaum Y, Fishbein MC, Peterson TM, Nagai T, Nishioka T, Siegel RJ. Enhancement of thrombolysis in vivo without skin and soft tissue damage by transcutaneous ultrasound. Thromb Res 1998; 89: 171-7.
10. Siegel RJ, Atar S, Fishbein MC, Brasch AV, Peterson TM, Nagai T, Pal D, Nishioka T, Chae JS, Birnbaum Y, Zanelli C, Luo H. Noninvasive, transthoracic, low-frequency ultrasound augments thrombolysis in a canine model of acute myocardial infarction. Circulation 2000; 101: 2026-9.
11. Suchkova V, Carstensen EL, Francis CW. Ultrasound enhancement of fibrinolysis at frequencies of 27 to 100 kHz. Ultrasound Med Biol 2002; 28: 377-82.
12. Laing ST, Moody M, Smulevitz B, Kim H, Kee P, Huang S, Holland CK, McPherson DD. Ultrasound-enhanced thrombolytic effect of tissue plasminogen activator-loaded echogenic liposomes in an in vivo rabbit aorta thrombus model - brief report. Arterioscler Thromb Vasc Biol 2011; 31: 1357-9.
13. Hudson M, Greenbaum A, Brenton L, Gibson CM, Siegel RJ, Reeves LR, Sala MF, McKendall G, Bluguermann J, Echt D, Ohman EM, Weaver WD. Adjunctive transcutaneous ultrasound with thrombolysis: results of the PLUS (Perfusion by ThromboLytic and UltraSound) trial. JACC Cardiovasc Interv 2010; 3: 352-9.
14. Nedelmann M, Eicke BM, Lierke EG, Heimann A, Kempski O, Hopf HC. Low-frequency ultrasound induces nonenzymatic thrombolysis in vitro. J Ultrasound Med 2002; 21: 649-56.
15. Alexandrov AV, Molina CA, Grotta JC, Garami Z, Ford SR, Alvarez-Sabin J, Montaner J, Saqqur M, Demchuk AM, Moyé LA, Hill MD, Wojner AW; CLOTBUST Investigators. Ultrasound enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004; 351: 2170-8.
16. Tsivgoulis G, Eggers J, Ribo M, Perren F, Saqqur M, Rubiera M, Sergentanis TN, Vadikolias K, Larrue V, Molina CA, Alexandrov AV. Safety and efficacy of ultrasound-enhanced thrombolysis: a comprehensive review and meta-analysis of randomized and nonrandomized studies. Stroke 2010; 41: 280-7.
17. Porter TR, Le Veen RF, Fox R, Kricsfeld A, Xie F. Thrombolytic enhancement with perfluorocarbon-exposed sonicated dextrose albumin microbubbles. Am Heart J 1996; 132: 964-8.
18. Nishioka T, Luo H, Fishbein MC, Cercek B, Forrester JS, Kim CJ, Berglund H, Siegel RJ. Dissolution of thrombotic arterial occlusion by high intensity, low frequency ultrasound and dodecafluoropentane emulsion: an in vitro and in vivo study. J Am Coll Cardiol 1997; 30: 561-8.
19. Wu Y, Unger EC, McCreery TP, Sweitzer RH, Shen D, Wu G, Vielhauer MD. Binding and lysing of blood clots using MRX-408. Invest Radiol 1998; 33: 880-5.
20. Xie F, Lof J, Matsunaga T, Zutshi R, Porter TR. Diagnostic ultrasound combined with glycoprotein IIb/IIIa-targeted microbubbles improves microvascular recovery after acute coronary thrombotic occlusions. Circulation 2009; 119: 1378-85.
21. Birnbaum Y, Luo H, Nagai T, Fishbein MC, Peterson TM, Li S, Kricsfeld D, Porter TR, Siegel RJ. Noninvasive in vivo clot dissolution without a thrombolytic drug: recanalization of thrombosed iliofemoral arteries by transcutaneous ultrasound combined with intravenous infusion of microbubbles. Circulation 1998; 97: 130-4.
22. Culp WC, Porter TR, Lowery J, Xie F, Roberson PK, Marky L. Intracranial clot lysis with intravenous microbubbles and transcranial ultrasound in swine. Stroke 2004; 35: 2407-11.
23. Culp WC, Flores R, Brown AT, Lowery JD, Roberson PK, Hennings LJ, Woods SD, Hatton JH, Culp BC, Skinner RD, Borrelli MJ. Successful microbubble sonothrombolysis without tissue-type plasminogen activator in a rabbit model of acute ischemic stroke. Stroke 2011; 42: 2280-5.
24. Porter TR, Xie F. Can transcranial ultrasound and microbubble therapy ever enter the mainstream in acute stroke therapy? Expert Rev Cardiovasc Ther 2012; 10: 549-51.
25. Alexandrov AV, Mikulik R, Ribo M, Sharma VK, Lao AY, Tsivgoulis G, Sugg RM, Barreto A, Sierzenski P, Malkoff MD, Grotta JC. A pilot randomized clinical safety study of sonothrombolysis augmentation with ultrasound-activated perflutren-lipid microspheres for acute ischemic stroke. Stroke 2008; 39: 1464-9.
26. Molina CA, Ribo M, Rubiera M, Montaner J, Santamarina E, Delgado-Mederos R, Arenillas JF, Huertas R, Purroy F, Delgado P, Alvarez-Sabín J. Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator. Stroke 2006; 37: 425-9.
27. Molina CA, Barreto AD, Tsivgoulis G, Sierzenski P, Malkoff MD, Rubiera M, Gonzales N, Mikulik R, Pate G, Ostrem J, Singleton W, Manvelian G, Unger EC, Grotta JC, Schellinger PD, Alexandrov AV. Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial. Ann Neurol 2009; 66: 28-38.
28. Hagisawa K, Nishioka T, Suzuki R, Takizawa T, Maruyama K, Takase B, Ishihara M, Kurita A, Yoshimoto N, Ohsuzu F, Kikuchi M. Enhancement of ultrasonic thrombus imaging using bubble liposomes containing perfluorocarbon targeted to activated platelet glycoprotein IIb/IIIa complex in a rabbit iliac artery. Int J Cardiol 2011; 152: 202-6.
29. Instruction Manual of AC Calorimetric Thermal Constant Measuring System. Yokohama, Japan: Sinku-Riko Inc., 1992.
30. Salazar AE. Experimental myocardial infarction. Induction of coronary thrombosis in the intact closed-chest dog. Circ Res 1961; 9: 1351-6.
31. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMl) trial: Phase I findings. N Engl J Med 1985; 312: 932-6.
32. Daffertshofer M, Gass A, Ringleb P, Sitzer M, Sliwka U, Els T, Sedlaczek O, Koroshetz WJ, Hennerici MG. Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial. Stroke 2005; 36: 1441-6.
33. Alonso A, Dempfle CE, Della Martina A, Stroick M, Fatar M, Zohsel K, Allémann E, Hennerici MG, Meairs S. In vivo clot lysis of human thrombus with intravenous abciximab immunobubbles and ultrasound. Thromb Res 2009; 124: 70-4.
34. Baron C, Aubry JF, Tanter M, Meairs S, Fink M. Simulation of intracranial acoustic fields in clinical trials of sonothrombolysis. Ultrasound Med Biol 2009; 35: 1148-58.
35. Ahmadi F, McLoughlin IV, Chauhan S, ter-Haar G. Bio-effects and safety of low-intensity, low-frequency ultrasonic exposure. Prog Biophys Mol Biol 2012; 108: 119-38.
36. Luo H, Fishbein MC, Bar-Cohen Y, Nishioka T, Berglund H, Kim CJ, Nagai T, Birnbaum Y, Siegel RJ. Cooling system permits effective transcutaneous ultrasound clot lysis in vivo without skin damage. J Thromb Thrombolysis 1998; 6: 125-31.
37. Storm G, Oussoren C, Peelers PAM, Barenholz Y. Tolerability of liposomes in vivo. In: Gregoriadis G, ed. Liposome Technology. Boca Raton, FL: CRC Press, 1993: 345-83.
38. Carpenter CP, Woodside MD, Kinkead ER, King JM, Sullivan LJ. Response of dogs to repeated intravenous injection of polyethylene glycol 4000 with notes on excretion and sensitization. Toxicol Appl Pharmacol 1971; 18: 35-40.
39. Lee TY, Lin CT, Kuo SY, Chang DK, Wu HC. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Res 2007; 67: 10958-65.
40. Chang DK, Lin CT, Wu CH, Wu HC. A novel peptide enhances therapeutic efficacy of liposomal anticancer drugs in mice models of human lung cancer. PLoS ONE 2009; 4: e4171.
41. Wei K, Mulvagh SL, Carson L, Davidoff R, Gabriel R, Grimm RA, Wilson S, Fane L, Herzog CA, Zoghbi WA, Taylor R, Farrar M, Chaudhry FA, Porter TR, Irani W, Lang RM. The safety of Definity and Optison for ultrasound image enhancement: a retrospective analysis of 78, 383 administered contrast doses. J Am Soc Echocardiogr 2008; 11: 1202-6.
42. Hutter JC, Luu HM, Mehlhaff PM, Killam AL, Dittrich HC. Physiologically based pharmacokinetic model for fluorocarbon elimination after the administration of an octafluoropropane-albumin microsphere sonographic contrast agent. J Ultrasound Med 1999; 18: 1-11.